

Adequate Disclosure

Axia Group, Inc.

Formerly=CyberAmerica Corp. until 12-00

Formerly=Canton Industrial Corp. (THE) until 6-96

Report Period Ending December 31

All information contained in this information and Disclosure Statement has been
complied to fulfill the disclosure requirements of Pink OTC Markets

Issuer's Initial Disclosure

NO DEALER, SALESMAN OR ANY OTHER PERSON HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION OR TO MAKE ANY REPRESENTATIONS NOT CONTAINED HEREIN IN CONNECTION WITH THE COMPANY. ANY REPRESENTATIONS NOT CONTAINED HEREIN MUST NOT BE RELIED UPON AS HAVING BEEN MADE OR AUTHORIZED BY THE COMPANY.

DELIVERY OF THIS INFORMATION FILE AT ANY TIME DOES NOT IMPLY THAT THE INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY TIME SUBSEQUENT TO THE DATE FIRST WRITTEN ABOVE.

COPIES OF THIS INFORMATION AND DISCLOSURE STATEMENT ARE AVAILABLE FROM THE ISSUER UPON REQUEST.

Table of Contents

Part A. General Company Information	6
Item I. Issuer: The Exact Name of the Issuer and Its Predecessor(s) (if any).....	6
Item II. The Address of the Issuer’s Principal Executive Offices.....	6
Item III. The Jurisdiction(s) and Date of the Issuer’s Incorporation or Organization	6
Part B. Share Structure	6
Item IV. The Exact Title and Class of Securities Outstanding	6
Item V. Par or Stated Value and Description of the Security	7
Item VI. The Number of Shares or Total Amount of the Securities Outstanding for Each Class of Securities Authorized.....	8
Part C. Business Information.....	9
Item VII. The Name and Address of the Transfer Agent	9
Item VIII. The Nature of the Issuer’s Business	9
The Nature of the Issuer’s Business.....	10
Item IX. Nature of Company Products or Services Offered	11
Item X. The Nature and Extent of the Issuer’s Facilities.....	17
Item XI. Market Description	18
Part D. Management Structure and Financial Information	21
Item XII. Names of the Chief Executive Officer, Members of the Board of	21
Directors, and Control Persons.....	21
Item XIII. Financial Information for the Issuer's most Recent Fiscal Period	22
Item XIV Financial Information for the Issuer's preceding two fiscal years	22
Item XV Beneficial Owners	23
Item XVI. The Name, Address, Telephone Number, and Email Address of Each of the Following outside Providers that Advise the Issuer on Matters Relating to the Operations, Business Development and Disclosure.....	24
Item XVII. Management’s Discussion and Analysis or Plan of Operation.....	24
Part E. Issuance History.....	25

Item XVIII. List of Securities Offerings and Shares Issued for Services in the Past Two Years	26
Part F. Exhibits.....	36
Item XIX. Material Events	36
Item XX. Articles of Incorporation and Bylaws	37
Item XXI. Purchases of Equity Securities by the Issuer and Affiliated Purchasers	37
Item XXII. Issuer’s Certifications	37

ISSUER INFORMATION AND DISCLOSURE STATEMENT

Axia Group, Inc.

Cautionary Note Regarding Forward-Looking Statements

Information set forth in this Initial Company Information and Disclosure Statement (the “Initial Disclosure Statement”) contains forward-looking statements, which involve a number of risks and uncertainties that could cause our actual results to differ materially from those reflected in the forward-looking statements. Forward-looking statements can be identified by use of the words “expect,” “project,” “may,” “might,” “potential,” and similar terms. Axia Group, Inc. (“AGIJ,” “we” or the “Company”) cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Forward-looking statements involve a number of risks, uncertainties or other factors beyond our control. These factors include, but are not limited to, our ability to implement our strategic initiatives, economic, political and market conditions and price fluctuations, government and industry regulation, competition and other factors. We undertake no obligation to update any forward looking statement, whether as a result of new information, future events or otherwise.

Part A. General Company Information

Item I. Issuer: The Exact Name of the Issuer and Its Predecessor(s) (if any)

The exact name of the issuer is Axia Group, Inc. (herein referred to as "Issuer") incorporated in the State of Nevada. Predecessor(s): Incorporated in the State of Nevada in March 1993. Formerly company was known as Canton Industrial Corp. (THE) until Jun 1996 and Cyber America Corp. until December 2000.

Item II. The Address of the Issuer's Principal Executive Offices

2360 Corporate Circle

Suite 400

Henderson, NV 89074

Phone: 613-667-3433

Website: <http://axiacorporation.com/>

Item III. The Jurisdiction(s) and Date of the Issuer's Incorporation or Organization

Company was originally incorporated on July 10, 1984, and changed our state of incorporation to Nevada on March 15, 1993. On December 6, 2000 AGIJ changed name from CyberAmerica Corporation to Axia Group, Inc.

Part B. Share Structure

Item IV. The Exact Title and Class of Securities Outstanding

Common Stock

Symbol: **AGIJ**

CUSIP: **05459Q883**

Effective December 31, 2011, there are 956,915,415 shares of the Issuer's common stock outstanding, par value \$0.00001.

Item V. Par or Stated Value and Description of the Security

A. The Current par value of the Issuer's common and preferred stock is \$0.00001

B. Common Stock rights. Each and every common share is entitled to one vote with no pre-emption rights and rights to dividends as the Issuer may deem appropriate from time to time. There are no provisions in the Issuer's bylaws or charter that would delay, defer or prevent a change in control of the Issuer.

C. Preferred Stock: The preferred stock may be issued from time to time in one or more series. The Board of Directors is authorized to fix the number of shares of preferred stock and to determine the designation of any series. The Board of Directors is also authorized to determine the rights, preference, privileges, and restrictions granted to or imposed on any wholly unissued series of preferred stock and, within the limits and restrictions stated in any resolution or resolutions of the Board of Directors originally fixing the number of shares constituting any series, to increase or decrease, (but not below the number of shares of such series then outstanding) the number of shares of any such series subsequent to the issue of shares of that series. No holder of any of the shares of any class of the corporation shall be entitled to as of right to subscribe for, purchase, or otherwise acquire any shares so any class of the corporation for which the corporation proposes to issue or any right or options which the corporation proposes to grant or for the purchase of any shares, bonds, securities, or obligations of the corporation which are convertible into or exchangeable for, or which carry any rights, to subscribe for, purchase or otherwise acquire shares of any class of the corporation; and any and all of such shares, bonds, securities, or obligations of the corporation, whether now or hereafter authorized or created may be issued, or may be reissued or transferred if the same have been reacquired and have treasury status, and any and all of such right and options may be granted by the board of directors to such persons, firms, corporation and associations, and for such lawful consideration, and on such terms, as the Board of Directors in its discretion may determine, without first offering the same, or any thereof, to any said holder.

**Item VI. The Number of Shares or Total Amount of the Securities
Outstanding for Each Class of Securities Authorized**

Common Stock

(i) Period end date	Yearend December 31. 2011	Yearend December 31. 2010	For the period ended September 30, 2010	For the period ended June 30, 2010
(ii) Number of shares authorized;	1,500,000,000	1,500,000,000 PV \$.001	1,500,000,000	500,000,000
(iii) Number of shares outstanding;	956,915,415 PV \$.00001	268,064,762 PV \$.001	138,064,762 PV \$.001	138,064,762 PV \$.001
(iv) Freely tradable shares (public float);	N/A	N/A	N/A	N/A
Total number of beneficial shareholders; and	N/A	N/A	N/A	N/A
Total number of shareholders on record.	390	390	N/A	N/A

Preferred Stock

(i) Period end date	For the period ended December 31. 2010	For the period ended December 31. 2010	For the period ended September 30, 2010	For the period ended June 30, 2010
(ii) Number of shares authorized;	500,000,000	500,000,000 PV \$.00001	250,000,000	N/A
(iii) Number of shares outstanding;	12,000,000 PV \$.00001	12,000,000 PV \$.00001	4,650,000 PV \$.00001	N/A
(iv) Freely tradable shares (public float);	N/A	N/A	N/A	N/A
Total number of beneficial shareholders; and	N/A	N/A	N/A	N/A
Total number of shareholders on record.	N/A	N/A	N/A	N/A

Part C. Business Information

Item VII. The Name and Address of the Transfer Agent

Transfer Online, Inc.

Transfer Agent, Investor Relations

512 SE Salmon Street

Portland, OR, 97214

503-227-2950

<http://www.transferonline.com>

TRANSFER ONLINE IS REGISTERED UNDER THE EXCHANGE ACT AND IS AN SEC APPROVED TRANSFER AGENT

Item VIII. The Nature of the Issuer's Business

The Issuer was incorporated in March 15, 1993. The Issuer's fiscal year ends on December 31.

The Issuer has had no bankruptcies or receiverships.

The Company

Company was originally incorporated on July 10, 1984, and changed our state of incorporation to Nevada on March 15, 1993. On December 6, 2000 AGIJ changed name from CyberAmerica Corporation to Axia Group, Inc.

Axia is a parent company to Collagenna Skin Care Products. Collagenna is part of a new generation of cosmetics that use only natural source, active ingredients.

No parabens and no animal testing. It is the ultimate in skin care for people who care about what they put onto their skin and into their bodies.

The Nature of the Issuer's Business

Issuer's primary SIC Code is 8059 - Nursing and personal care, misc.

President - MICHAEL ARNKVARN			
Address 1:	2360 CORPORATE CIRCLE - SUITE 400	Address 2:	
City:	HENDERSON	State:	NV
Zip Code:	89074-7722	Country:	
Status:	Active	Email:	
Director - PHILLIP WELSH			
Address 1:	2360 CORPORATE CIRCLE - SUITE 400	Address 2:	
City:	HENDERSON	State:	NV
Zip Code:	89074-7722	Country:	
Status:	Active	Email:	
Secretary - PHILLIP WELSH			
Address 1:	2360 CORPORATE CIRCLE - SUITE 400	Address 2:	
City:	HENDERSON	State:	NV
Zip Code:	89074-7722	Country:	
Status:	Active	Email:	
Treasurer - PHILLIP WELSH			
Address 1:	2360 CORPORATE CIRCLE - SUITE 400	Address 2:	
City:	HENDERSON	State:	NV
Zip Code:	89074-7722	Country:	
Status:	Active	Email:	

Item IX. Nature of Company Products or Services Offered

Axia Group, Inc. main subsidiary Collagenna Skin Care Products is a natural health products and cosmetics company. Our main products provide anti-aging skin care solutions that visibly repair and rejuvenate.

Collagenna Skin Care products are the result of extensive research and development by Canadian scientists and are created using pure, natural and odourless 100% soluble Native Marine Collagen.

Collagenna Skin Care Products is a natural health products and cosmetics company. Our main products provide anti-aging skin care solutions that visibly repair and rejuvenate.

Collagenna Skin Care products are the result of extensive research and development by Canadian scientists and are created using pure, natural and odourless 100% soluble Native Marine Collagen. Designed to nourish, repair and rejuvenate the essential ingredients of the skin, Collagenna's unique skin care method replenishes proteins, lipids and sugars. Products include serums, moisturizers, cleansers, exfoliants and body care creams.

Collagenna's products also include Melem Secret neutraceuticals that provide an all-natural solution to improve the quality of your skin from the inside out. The supplements work alone or in combination with skin-care products to achieve noticeable results and a healthy glow.

Business description

Collagenna is part of a new generation of cosmetics that use only natural source, active ingredients. No parabens and no animal testing. It is the ultimate in skin care for people who care about what they put onto their skin and into their bodies.

The Collagenna Skin Care Products program makes feeling good about your skin easy to do. Created using pure, natural and odorless 100% soluble Native Marine Collagen, Collagenna Skin Care Products are the result of extensive research and development by Canadian scientists. Designed to nourish, repair and rejuvenate the essential ingredients of the skin, Collagenna's unique skin care method replenishes proteins, lipids and sugars.

Used as directed, Collagenna Skin Care Products:

- Increase hydration levels
- Penetrate and repair aging skin
- Lessen fine lines
- Improve skin texture and elasticity
- Tighten pores
- Reduce inflammation

Collagenna Skin Care Products has an amazing Dual Platform Revenue Generator Opportunity that is high profit and volume.

The primary growth in the anti-aging market is on-set of the baby boom generation, now at mature consumer status, and their increasing desire to LOOK and FEEL good.

The result is a phenomenal growth because these consumers are willing to pay top dollar for quality products and treatments that they consider effective.

Microcurrent has been used safely on patients since the 1940's. Over the last 10 years utilizing the expertise of MD's, technologists, and a NASA engineer, our program developed a proprietary waveform, considered a break-through in non-invasive anti-aging procedures.

The result is the ability to provide treatments that obtain MCR (Maximum Cosmetic Recovery) for patients and also address the five major concerns of consumers and patients.

- Harmful side effects - None
- Pain level - None
- Downtime - None
- Affordable - Yes
- Generate revenues - Yes
- Effectiveness - 100%

Muscle re-education: compared to previous microcurrent technology, the Chiro950 "Unique (7) Waveform Sequencer" achieves twice the results in half the time.

In fact, our last 10 years of research was dedicated so you can get results the first 20 minutes.

It is our most closely guarded proprietary feature providing noticeable results on patients the first treatment.

Collagenna's Revolutionary Collagen Infusion Technology

The Jet-Clear System custom handpiece creates a supersonic two-phase jet consisting of microdroplets of air and water. The pressure accelerates the droplets velocity to 200m per second. When the micronized, fast-moving droplets form, the jet stream strikes the skin, and the kinetic energy of the droplets peels off the outer layers of dead skin.

The pressure differential created by the jet stream opens up micro channels to dramatically enhance the infusion of skin rejuvenating molecules into the dermis.

During treatment skin temperature drops by 5-8 degrees Celsius. This, in turn, stimulates the body's thermoregulation system, increases blood circulation to the skin, and increases calorie consumption for several minutes.

Jet-Clear's ability to immediately improve skin turgor, circulation, and humidity creates the ideal conditions for further healing and refines the skin structure. Post-operative use of Jet-M accelerates skin reconstruction through deep and intensive moisturizing and cleansing, thereby stimulating the recovery process.

Jet-Clear Features

- Painless peeling
- Immediate and long-term wrinkle reduction
- Widens micro channels momentarily to enhance infusion
- Fights acne naturally without chemicals
- Instantly delivers soft, hydrated and supple skin
- Ability to perfuse skin supplements transutaneously without needles
- Produces no skin shedding

Jet-M can be used on any skin surface of the body and face, including the top of the head, total eye area and hands and feet.

Collagenna Collagen Revolutionary Technology, the Jet Clear machine will facilitate collagen infusion by the use of this machine's technology.

Collagenna just finalized a private label deal with a distributor in Ireland. After studying the new EU regulations regarding cosmetic importations by foreign nationals, Collagenna management decided that it was in both parties best interest to develop a strategic relationship involving a private label brand. The first products are being shipped early next week and company intends to inform shareholders when this line is ready for its initial launch.

Product Concept

Collagen, along with keratin, is responsible for skin strength and elasticity. As the main component of the body's fascia, cartilage, ligaments, tendons, bone, and skin, collagen has great tensile strength. But the process of aging can decrease our body's natural production of collagen in the skin, causing it to thin, sag, and wrinkle.

Collagenna recognizes this and has developed a line of skin care products that reintroduce collagen to the body. Created using 100% Soluble Native Marine Collagen this product line penetrates the skin naturally and promotes its repair.

Collagenna Skin Care Products - a Natural Self Foaming Cleanser, Peptide Serum with Hyaluronic Acid, VivreSkinPlus Marine Collagen, VivreSkin Day Cream, Vivreskin Night Cream, VivreSkinCollabase Cream, and Vivreskin Body Dermal Care cream cleanse and nourish aging skin to make it softer and smoother.

The Collagenna Papaya Enzymatic Exfoliant with Peeling Beads promotes healthy and well conditioned skin. Collagenna Micro Algae Paste is a clinical exfoliant that helps to tighten pores and reduce inflammation. It is pure micro algae in an unaltered state, rich in Omega 3, minerals, vitamins and filtered sea water.

Exclusive to the Collagenna's product line is a serum that uses Collagenna's Penta Peptide technology to stimulate your own natural collagen growth.

"Our peptide serum has a high concentration of Penta-Peptides along with Hyaluronic Acid", says Michael Arnkvorn, President, Collagenna Skin Care Products. "Penta Peptides are small chains of five amino acids which have been shown to easily penetrate the skin. Once in the dermis they actually stimulate the production of one's own collagen."

Included in the moisturizing formulations are Omega 3 natural antioxidants and Emblica.

Collagenna Skin Care Products/Melem Secret has recently introduced its latest product, DermaMagie.

DermaMagie combines Collagenna's Pure Marine Collagen with an herbal extract from Nobel Chinese medicine which acts as a natural replacement to hyaluronic acid. This revolutionary skin gel leaves the skin feeling silky smooth, improving hydration and resulting in younger, healthier skin.

DermaMagie is a very strategic product for us. It is a high quality natural product which can be sold as a 'stand-alone' serum; it has great benefits and gives instant results.

For the moment Derma Magie is available at all of Collagenna's Skin Clinics as well as online www.collagenna.com. Further, product development is ongoing and some new products are slated to be introduced later this year. Shareholders will be informed as they become available.

Collagenna Skin Care Products specializes in Anti-aging products with an emphasis on Collagen stimulation both topically and internally. The company sells its products mainly through its specialized skin care clinics and its ever expanding distribution network.

Collagenna has an extensive worldwide network, and is committed to becoming an international corporation. Collagenna has international distribution agreements with the United States, the Middle East, Norway, Malaysia, Canada, Brazil and Switzerland. Collagenna also has plans to distribute its products in six new countries by 2011, and is emphasizing expansion in the Middle East. Distribution opportunities exist throughout many sectors, including esthetician and skin care clinics, retail outlets, health practitioners, gyms and personal trainers.

In the US, Collagenna has partnered with the Texas Beauty Institute of the Dallas/Fort Worth Area. The Texas Beauty Institute (TBI) is a leader in the field of non-invasive cosmetic recovery solutions. TBI will distribute the Collagenna product line to other clinics and to retail customers.

In Scandinavia, Collagenna holds an exclusive distribution agreement with Propolife, a MLM company that has over 6000 members. Propolife is planning further expansion into Europe. This expansion will help increase Collagenna's sales in Europe.

Collagenna Skin Care Products also has an exclusive distribution agreement with the beauty products distributor, Just Nailz& Beauty Supplies, in Calgary, Canada. Just Nailz& Beauty Supplies is a professional beauty wholesaler and training centre. Its professional beauty products are sold to salons and beauty schools in Western Canada and Arizona.

Collagenna is working with its partner, Collagenna do Brasil, to distribute its products to the South American market.

Alphaderm Body and Wellness, a Swiss company, recently introduced the Collagenna line to their market. Alphaderm sells body products and Collagenna skin care products to specialized beauty clinics across Switzerland.

Industry Overview:

Even during tough economic times, the cosmetic industry has proved resilient as customers continue to spend on skin care products, particularly anti-aging facial skin products.

Collagenna's natural product focus poises the company to benefit from the largest growth in the sector.

In 2007, the global skin care market grew by 4.1% and reached a value of \$49.5 billion. Despite a minimal decline in 2009, the market research company NPD predicts a return to growth. Forecasts calculate a market value of \$58.2 billion by 2012. Anti-aging products represented 62% of the prestige facial skincare market in 2009, with NPD's point of sale data estimating its worth at \$1.2 billion. NPD's Women's Skincare In-Depth Consumer Report, which surveyed over 6,000 consumers, revealed that anti-aging is the key motivator when it comes to buying facial skincare products. Most respondents (53%) revealed that the benefits of anti-aging were very or extremely important to them.

The natural and organic sector is the fastest growing in the North American cosmetics & toiletries industry, with sales increasing by 20% a year. Today's consumers are increasingly demanding green products, and in response, large cosmetic companies, retailers, drugstores and pharmacies across North America and Western Europe are incorporating natural and organic cosmetics into their product offerings.

Item X. The Nature and Extent of the Issuer's Facilities

Head Office:

Collagenna Skin Care Products Inc

16 Edward Street, Suite 53

Arnprior, Ontario

K7S 3W4

Tel: 613-667-3433

Toll Free: 866-649-9831

Email: info@collagenna.net

Collagenna Skin Care Clinics:

Located in:

Village Health Food

640 Eglinton Ave., West

Mississauga, ON L5R 3V2

416-235-1084

Located in:

Port Credit Village Pharmacy

225 Lakeshore Rd. E.

Mississauga, ON L5G 1G8

416-840-0372

Located in:

Village Health Food

229 Queen St. E.

Brampton, ON L6W 2B5

Item XI. Market Description

The skin care industry is a multi-billion dollar business, estimated to be worth US 43 billion per year. It has steadily grown in the past years, and is expected to grow 6.8% more this year. Europe and the US are the biggest markets of the industry, accounting for over 50% of global skin care sales.

The primal desire of humans to remain young forever so long has groomed and nurtured a goliath of an anti-aging industry worldwide. The market for anti-aging health, and appearance products posts sanguine growth patterns for the upcoming years, backed largely by the affluent aging baby boomers with high levels of disposable incomes. Anti-aging products market is traditionally resilient to economic cycles, given consumers' unchanging desire to look young and healthy, and the importance accorded to health, and well-being. The propensity to spend on skincare is not hugely impacted by a slowdown, rather consumer preferences during these periods tend to shift towards lower priced mass-market products. Product effectiveness will become an important factor as consumers begin to seek visual, sensory, and functional benefits from products. Benefiting from significant investments both in terms of product innovation and marketing, worldwide market for anti-aging products has emerged into a lucrative industry churning out top dollars for market participants.

Growth in the anti-aging product categories varies by product, with least perceptible dent to be witnessed in the health maintenance segment. World market for Anti-Aging Products for Health Maintenance is dominated by the US and Europe, as stated by the recent report published by Global Industry Analysts, Inc. In the relatively less essential appearance enhancement products market, premium products are expected to take the brunt of lower consumer disposable incomes, and reduction in household wealth. Anti-aging products that include natural, and organic ingredients such as botanical herbs, and vitamin E are rising in popularity. Market for Anti-Aging Products for Appearance Enhancement in United States is expected to be more than US\$5.0 billion by 2015. Increasing consumer concerns regarding harmful skin cancer and wrinkles caused by recurrent exposure to sun is expected to lead to introduction of multipurpose products with dual benefits of moisturizing and sun protection.

Anti-Aging Products: A Global Market Report Like any other industry, anti-aging products also contend with skepticism, and conflicting clinical research results surrounding the actual health and appearance benefits of many widely publicized compounds, and ingredients. The oncoming regulatory reformation brings with it a mixed bag of benefits and challenges. While the industry

may be necessitated to provide authentic products, and services thereby benefiting the consumer, smaller companies are likely to take the exit route due to lack of scientific expertise, and financial funding leading to a shakeout in the industry. Today, manufacturers to avoid the regulatory ire develop, and market cosmeceuticals by incorporating only pharmaceutical ingredients approved by the FDA i.e. retinol or minoxidil, antioxidants and natural extracts which have withstood the test of time, and which do not require the FDA's approval.

People spend a lot of money each year in the quest of eternal youth and beauty, and that number is only going to get bigger as younger people hope to stave off the aging process.

According to an infographic posted on TermLifeInsurance.org, the value of the industry in 2011 was estimated at \$80-billion, and is set to reach \$114-billion by the year 2015 if current trends continue.

ABOUT THE MARKET

The opportunities in the Anti-Aging market are vast, with the global market estimated to be worth \$292 billion by 2015. Furthermore, the proportion of the world's population aged 60 or over currently stands at 10%, but this figure is expected to more than double to 22% by 2050.

One of the World Health Organization's "ten global health targets for the 21st century" is "to achieve an increase in life expectancy and in the quality of life for all." It is predicted that, by the year 2029, advancements in stem cell research, therapeutic cloning, and nanotechnology will be harnessed into applications that improve and extend the human life span. In this manner, Anti-Aging Medicine is anticipated to have a profound and permanent impact on the future of preventative health care.

The global skincare market grew by 4.5% in 2010 to reach a value of \$78,131 million.

In 2015, the global skincare market is forecast to have a value of \$94,694.6 million, an increase of 21.2% since 2010.

The global skincare market grew by 4.1% in 2010 to reach a volume of 11,016.8 million units.

In 2014, the global skincare market is forecast to have a value of \$80,127.6 million, an increase of 21.4% since 2009.

In 2014, the global skincare market is forecast to have a volume of 11,016.9 million units, an increase of 18.8% since 2009.

In 2015, the global skincare market is forecast to have a volume of 13,225.3 million units, an increase of 20% since 2010.

Facial care is the largest segment of the global skincare market, accounting for 64.1% of the market's total value.

Asia-Pacific accounts for 44% of the global skincare market value

US demand for cosmeceutical products is expected to increase 5.8 percent annually through 2015. Injectables and skin care products will see the fastest growth, based on anti-aging benefits. Among chemicals, antioxidants will remain the largest category, while botanicals continue to see the fastest gains.

GROWTH POTENTIAL

The global beauty and wellness market size is estimated at approximately \$500 billion. THE ANTI-AGING PORTION OF THE MARKET IS ESTIMATED AT APPROXIMATELY \$100 BILLION, WITH ANNUAL GLOBAL GROWTH RATES BETWEEN 8% AND 10% OVER THE NEXT DECADE, with Asia-Pacific and North America representing the largest growth geographies.

Global Anti-Aging Market Growth					
	2-Year Projected Growth Rates				7-Year Projected Growth Rate
Market	2009	2011	2013	2015	
United States: \$ Billions	34,848.88	42,207.74	50,626.82	58,734.66	
United States: % Growth	19.17%	21.12%	19.95%	16.01%	76.25%
Europe: \$ Billions	31,707.54	37,932.44	44,761.99	52,308.57	
Europe: % Growth	18.94%	19.63%	18.00%	16.86%	73.43%
Japan: \$ Billions	11,389.28	13,555.79	15,965.13	18,556.37	
Japan: % Growth	19.30%	19.02%	17.77%	16.23%	72.33%
Asia-Pacific: \$ Billions	9,322.09	11,221.25	13,566.91	16,444.23	
Asia-Pacific: % Growth	19.72%	20.37%	20.90%	21.21%	82.20%

Despite some trade down during the recession, premium skin care is set to see the biggest increase in value size of any premium segment, with \$2.6 billion predicted to be added over 2009–2014, equating to 40% of absolute growth in the entire premium beauty industry. This performance will be driven by strong demand for premium skin care in Asia, especially China. Even in Western markets such as the U.S., sales of premium antiagers have remained comparatively buoyant as consumers have, evidently, attached greater importance to fighting the aging process than other areas of beauty, and the perception of a link between price and efficacy remains strong for many consumers despite evidence to the contrary. Despite declines in many other areas of skin care, recession-hit France saw 3% value growth in premium antiagers in 2009, up from 1% in 2008, according to Euromonitor

he U.S. skin care category is expected to swell by \$264 million 2009–2014, largely driven by nourishers/antiagers. While cleansers and acne treatments, notably body and facial moisturizers, have reached maturity and are expected to see sales growth slow or even decline, the nourishers/antiagers category shows no signs of slowing down. Demand for antiaging products will be driven by the aging U.S. population, with the number of consumers over 50 set to rise by more than 10 million 2009–2014.

Part D. Management Structure and Financial Information

Item XII. Names of the Chief Executive Officer, Members of the Board of Directors, and Control Persons

Michael Arnkvarn has been President of Axia Group, Inc., since August 2010. Mr. Arnkvarn brings 30 years of business experience to Collagenna Skin Care Products. He has significant experience in the Health Food Industry having owned and operated 2 health foods stores over 7 years in the early 1990s. He has extensive management and marketing experience in the environmental field having held the positions of General Manager and VP of Operations in several privately owned corporations. In 2004, he established Collagenna Skin Care Products and has since transitioned the business from a distributor of imported products to a manufacturer with its own brand recognition.

Legal/Disciplinary History

None of the Officers, Directors or Beneficial Shareholders has, in the past five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);
2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;
3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities

regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person's involvement in any type of business or securities activities

Disclosure of Family Relationships

There may be family relationships existing among and between the issuer's officers, directors and shareholders; the shareholders and the issuer, its predecessors, its present and prior officers and directors, and other shareholders.

Disclosure of Related Party Transactions

There are no related party transactions involving the issuer in which (i) the amount involved exceeds the lesser of \$120,000 or one percent of the average of the Issuer's total assets at year-end for its last three fiscal years and (ii) any related person had or will have a direct or indirect material interest.

Disclosure of Conflicts of Interest

There are no Conflicts of Interest with the Issuer.

Item XIII. Financial Information for the Issuer's most Recent Fiscal Period

Financial information of the Issuer for the Issuer's most recent fiscal period dates December 31, 2011. It is yearend report

As such, the financial reports include balance sheet, statement of income and comprehensive income, and statement of cash flows, and statement of changes in shareholders' equity, as amended.

Item XIV Financial Information for the Issuer's preceding two fiscal years

Financial information is filed with the Securities and Exchange Commission EDGAR system at <http://sec.gov/Archives/edgar/data/788738/000078873810000005/agij10q.txt> and is incorporated by reference.

Item XV Beneficial Owners

The following table presents the name, address and shareholdings of all persons beneficially owning more than five percent (5%) of any class of the Issuer's equity securities as of 2005. To the extent not otherwise disclosed, if any of the above shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

<u>Owner</u>	<u>Filings</u>	<u>Transaction Date</u>	<u>Type of Owner</u>
<u>AXIA GROUP INC/UT</u>	<u>0000788738</u>	2004-07-22	10 percent owner
<u>Regan Jody</u>	<u>0001293962</u>	2004-06-17	director, 10 percent owner, officer: President
<u>SURBER RICHARD D</u>	<u>0001017925</u>	2003-08-22	director, 10 percent owner, officer: President & Director Axia
<u>HUDSON CONSULTING GROUP INC</u>	<u>0001070544</u>	2003-08-11	10 percent owner
<u>EINHORN GERALD</u>	<u>0001234483</u>	2003-05-02	director, officer: Vice-President

Item XVI. The Name, Address, Telephone Number, and Email Address of Each of the Following outside Providers that Advise the Issuer on Matters Relating to the Operations, Business Development and Disclosure

Investment Banker: N/A

Promoters: N/A

Securities Counsel: N/A

Investor Relations Consultant:

Mina Mar Group

5155 Spectrum Way Unit #5

Mississauga, Ontario

L4W 5A1

Canada

Advisor:

Mina Mar Group – OTC Verify

Email: info@otcverify.com

Phone: (800) 723-9746

5155 Spectrum Way Unit #5

Mississauga, Ontario

L4W 5A1

Canada

Item XVII. Management's Discussion and Analysis or Plan of Operation

A. Plan of Operation

Through recent press releases Axia Group and Collagenna Skin Care announced the launch of the Canada wide national campaign starts on May 6, 2012.

This is a National Campaign across Canada for the company. Collagenna ran a similar ad with the aforementioned company's competitor (a much smaller player) where Collogena enjoyed a brisk 350 unit sales benefit experience. Collagenna has expectations of selling 350-500 units in this campaign on a low end.

Collagenna is anticipating to run a second campaign during the following week(s). Other plans include a charity event the company is organizing locally at the company owned / operated store www.bit.ly/AGIJ-Charity-Drive

In Toronto Collagenna operate 3 clinics which are situated in an existing business (the Village Health Food Group) which allows company to solicit existing clients who come to shop in these stores. We call this concept, Collagenna's Boutique Clinic concept. Collagenna felt that it was also important to develop a 'stand alone' concept which is our new Ottawa location. We are very pleased with the results of our new store and it will allow us to expand the options which we can offer to interested parties in our business concept.

We have plans to open 2 more corporate stores this summer and we are in final negotiations with interested parties to bring our concept to the Middle East and the USA.

Collagenna just launched the opening of new facilities in Stittsville (Ottawa), Ontario. The new facilities are situated in a retail environment and include a full store front along with a treatment room offering Collagenna's Natural Anti-Aging services.

A panoramic view of the new store facilities can be viewed at www.collagenna.com under the Stittsville clinic tab.

Off-Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company's financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Part E. Issuance History

Item XVIII. List of Securities Offerings and Shares Issued for Services in the Past Two Years

Nature of the Offering	Jurisdiction	Number of Shares Offered	Number of Shares Sold	Price Offered (Amount Paid to Issuer)	Trading Status of Share	Certificates Contain Legend (1)Securities Act (2)Referring to Restriction
N/A						

Since the last day of the Issuer's most recent fiscal year:

Nature of the Offering	Jurisdiction	Number of Shares Offered	Number of Shares Sold	Price Offered (Amount Paid to Issuer)	Trading Status of Share	Certificates Contain Legend (1)Securities Act (2)Referring to Restriction
N/A						

Preferred Stocks

Nature of the Offering	Jurisdiction	Number of Shares Offered	Number of Shares Sold	Price Offered (Amount Paid to Issuer)	Trading Status of Share	Certificates Contain Legend (1)Securities Act (2) Referring to Restriction
N/A						

Since the last day of the Issuer’s most recent fiscal year

Nature of the Offering	Jurisdiction	Number of Shares Offered	Number of Shares Sold	Price Offered (Amount Paid to Issuer)	Trading Status of Share	Certificates Contain Legend (1)Securities Act (2) Referring to Restriction
N/A						

RISK RELATED TO OUR BUSINESS

THERE IS NO ASSURANCE THAT OUR FUTURE OPERATIONS WILL RESULT IN REVENUES OR PROFITS. IF WE CANNOT GENERATE SUFFICIENT REVENUES TO OPERATE PROFITABLY, THEN WE MAY SUSPEND OR CEASE OUR OPERATIONS AND YOU COULD EVEN LOSE YOUR ENTIRE INVESTMENT IN OUR COMMON STOCK.

The success of our future operations is dependent upon our ability to carry out our planned activities, fund our operations and compete effectively with other similar businesses. We cannot guarantee that we will be successful in generating revenues sufficient to cover our operating costs and overhead or achieve profitability. Our failure to achieve profitability may cause us to suspend or cease our operations.

THE COMPANY MAY BE SUBJECT TO FURTHER GOVERNMENT REGULATION WHICH WOULD ADVERSELY AFFECT OUR OPERATIONS.

Although we will be subject to the reporting requirements under the Exchange Act, management believes we will not be subject to regulation under the Investment Company Act of 1940, as amended ("Investment Company Act"), since we will not be engaged in the business of investing or trading in securities. If we engage in business combinations which result in our holding passive investment interests in a number of entities, we could be subject to regulation under the Investment Company Act. If so, we would be required to register as an investment company and could be expected to incur significant registration and compliance costs. We have obtained no formal determination from the SEC as to our status under the Investment Company Act and, consequently, violation of the Investment Company Act could subject us to material adverse consequences.

RISKS RELATED TO AN INVESTMENT IN OUR SECURITIES OUR COMMON STOCK IS CURRENTLY TRADED IN THE PINK SHEETS. AND IS A "PENNY STOCK" AND, AS SUCH, THE MARKET FOR OUR COMMON STOCK IS LIMITED BY CERTAIN SEC RULES APPLICABLE TO PENNY STOCKS.

As long as the price of our common stock remains below \$5.00 per share, our shares of common stock are likely to be subject to certain "penny stock" rules promulgated by the SEC. Those rules impose certain sales practice requirements on brokers who sell penny stock to persons other than established customers and accredited investors (generally, an institution with assets in excess of \$5,000,000 or an individual with a net worth in excess of \$1,000,000). For transactions covered by the penny stock rules, the broker must make a special suitability

determination for the purchaser and receive the purchaser's written consent to the transaction prior to the sale. Furthermore, the penny stock rules generally require, among other things, that brokers engaged in secondary trading of penny stocks provide customers with written disclosure documents, monthly statements of the market value of penny stocks, disclosure of the bid and asked prices of penny stocks and disclosure of the compensation to the brokerage firm and disclosure of the sales person working for the brokerage firm. These rules and regulations make it more difficult for brokers to sell shares of our common stock and limit the liquidity of our shares.

TRADING IN OUR SECURITIES COULD BE SUBJECT TO EXTREME PRICE FLUCTUATIONS THAT COULD ADVERSELY AFFECT YOUR INVESTMENT.

Historically speaking, the market prices for securities of small publicly traded companies have been highly volatile. Publicized events and announcements may have a significant impact on the market price of our common stock.

In addition, the stock market from time to time experiences extreme price and volume fluctuations that particularly affect the market prices for small publicly traded companies and which are often unrelated to the operating performance of the affected companies.

THE COMPANY MAY BE SUBJECT TO CERTAIN TAX CONSEQUENCES IN OUR BUSINESS, WHICH MAY INCREASE OUR COST OF DOING BUSINESS.

We may not be able to structure our acquisition to result in tax-free treatment for the companies or their stockholders, which could deter third parties from entering into certain business combinations with us or result in being taxed on consideration received in a transaction. Currently, a transaction may be structured so as to result in tax-free treatment to both companies, as prescribed by various federal and state tax provisions. We intend to structure any business combination so as to minimize the federal and state tax consequences to both us and the target entity; however, we cannot guarantee that the business combination will meet the statutory requirements of a tax-free reorganization or that the parties will obtain the intended tax-free treatment upon a transfer of stock or assets. A non-qualifying reorganization could result in the imposition of both federal and state taxes that may have an adverse effect on both parties to the transaction.

THE COMPANY INTENDS TO ISSUE MORE SHARES IN ADDITIONAL MERGER OR ACQUISITION, WHICH MAY RESULT IN SUBSTANTIAL DILUTION TO EXISTING SHAREHOLDERS.

Any future merger or acquisition may result in the issuance of additional securities without stockholder approval and may result in substantial dilution in the percentage of our common stock held by our then existing stockholders. Moreover, the common stock issued in any such merger or acquisition transaction may be valued on an arbitrary or non-arm's-length basis by our management, resulting in an additional reduction in the percentage of common stock held by our then existing stockholders. Our Board of Directors has the power to issue any or all of such authorized but unissued shares without stockholder approval. To the extent that additional shares of common stock or preferred stock are issued in connection with a business combination or otherwise, dilution to the interests of our stockholders will occur and the rights of the holders of common stock might be materially and adversely affected.

BECAUSE WE MAY SEEK TO COMPLETE ADITIONAL BUSINESS COMBINATION THROUGH A "REVERSE MERGER," FOLLOWING SUCH A TRANSACTION WE MAY NOT BE ABLE TO ATTRACT THE ATTENTION OF MAJOR BROKERAGE FIRMS.

Additional risks may exist since we will assist a privately held business to become public through a "reverse merger." Securities analysts of major brokerage firms may not provide coverage of our Company since there is no incentive to brokerage firms to recommend the purchase of our common stock. No assurance can be given that brokerage firms will want to conduct any secondary offerings on behalf of our post-merger company in the future.

WE CANNOT ASSURE YOU THAT FOLLOWING A BUSINESS COMBINATION WITH AN OPERATING BUSINESS, OUR COMMON STOCK WILL BE LISTED ON NASDAQ OR ANY OTHER SECURITIES EXCHANGE.

Following a certain business combination, we may seek the listing of our common stock on NASDAQ or the American Stock Exchange. However, we cannot assure you that following such a transaction, we will be able to meet the initial listing standards of either of those or any other stock exchange, or that we will be able to maintain a listing of our common stock on either of those or any other stock exchange. After completing a business combination, until our common stock is listed on the NASDAQ or another stock exchange, we expect that our common stock would be eligible to trade on the OTC Bulletin Board, another over-the-counter quotation system, or on the "pink sheets," where our stockholders may find it more difficult to dispose of shares or obtain accurate quotations as to the market value of our common stock. In addition, we would be subject to an SEC rule that, if it failed to meet the criteria set forth in such rule, imposes various practice requirements on broker-dealers who sell securities governed by the

rule to persons other than established customers and accredited investors. Consequently, such rule may deter broker-dealers from recommending or selling our common stock, which may further affect its liquidity. This would also make it more difficult for us to raise additional capital following a business combination.

SUBSTANTIAL SALES OF OUR COMMON STOCK MAY IMPACT THE MARKET PRICE OF OUR COMMON STOCK.

Future sales of substantial amounts of our common stock, including shares that we may issue upon exercise of options and warrants, and the resale of shares by investors who have registration rights, could adversely affect the market price of our common stock. Furthermore, if we raise additional funds through the issuance of common stock or securities convertible into our common stock, the percentage ownership of our shareholders will be reduced and the price of our common stock may fall.

WE DO NOT EXPECT TO PAY DIVIDENDS FOR THE FORESEEABLE FUTURE.

We will use any earnings generated from our operations to finance our business and will not pay any cash dividends to our shareholders in the foreseeable future.

ISSUING PREFERRED STOCK WITH RIGHTS SENIOR TO THOSE OF OUR COMMON STOCK COULD ADVERSELY AFFECT HOLDERS OF COMMON STOCK.

Our charter documents grant our board of directors the authority to issue various series of preferred stock without a vote or action by our shareholders. Our board also has the authority to determine the terms of preferred stock, including price, preferences and voting rights. The rights granted to holders of preferred stock may adversely affect the rights of holders of our common stock. For example, a series of preferred stock may be granted the right to receive a liquidation preference - a pre-set distribution in the event of a liquidation that would reduce the amount available for distribution to holders of our common stock. In addition, the issuance of preferred stock could make it more difficult for a third party to acquire a majority of our outstanding voting stock. As a result, common shareholders could be prevented from participating in transactions that would offer an optimal price for their shares.

IF OUR FUTURE PLANS INCLUDE BECOMING A REPORTING COMPANY, WE WILL BE SUBJECT TO THE PERIODIC REPORTING REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934 WHICH WILL REQUIRE US TO INCUR AUDIT FEES AND LEGAL FEES IN CONNECTION WITH THE PREPARATION OF SUCH REPORTS. THESE COSTS COULD REDUCE OR ELIMINATE OUR ABILITY TO EARN A PROFIT.

We will be required to file periodic reports with the Securities and Exchange Commission pursuant to the Securities Exchange Act of 1934 and the rules and regulations promulgated there under. In order to comply with these regulations, our independent registered public accounting firm must review our financial statements on a quarterly basis and audit our financial statements on an annual basis. Moreover, our legal counsel has to review and assist in the preparation of such reports. The costs charged by these professionals for such services cannot be accurately predicted at this time because of factors such as the number and type of transactions that we engage in and the complexity of our reports cannot be determined at this time and will have a major effect on the amount of time to be spent by our auditors and attorneys. However, the incurrence of such costs will obviously be an expense to our future operations and could have a negative effect on our ability to meet our overhead requirements and earn a profit. We may be exposed to potential risks resulting from new requirements under Section 404 of the Sarbanes-Oxley Act of 2002. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported financial information and the trading price of our common stock could drop significantly. The Company may provide a method for a foreign or domestic privately held company to become a reporting company whose securities are qualified for trading in the United States securities markets, such as the New York Stock Exchange ("NYSE"), NASDAQ, American Stock Exchange ("AMEX") or the OTC Bulletin Board, and, as a vehicle to investigate and, if such investigation warrants, acquire a target company or business seeking the perceived advantages of being a publicly held reporting company. The Company's principal business objective for the next 12 months and beyond will be to achieve long-term growth potential through a combination with a business rather than immediate, short-term earnings. The Company will not restrict its potential candidate target companies to any specific industry or geographical location and, thus, may acquire or merge with any type of business, domestic or foreign.

WE MAY BE EXPOSED TO POTENTIAL RISKS RESULTING FROM NEW REQUIREMENTS UNDER SECTION 404 OF THE SARBANES-OXLEY ACT OF 2002.

Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, we will be required, beginning with our next annual report, to include in our annual report our assessment of the effectiveness of our internal control over financial reporting as of the end of such fiscal years. Furthermore, our independent registered public accounting firm will be required to attest to whether our assessment of the effectiveness of our internal controls over financial reporting is fairly stated in

all material respects and separately report on whether it believes we have maintained, in all material respects, effective internal control over financial reporting as of the end of our fiscal years. We do not have a sufficient number of employees to segregate responsibilities and may be unable to afford increasing our staff or engaging outside consultants or professionals to overcome our lack of employees. We have not yet begun our assessment of the effectiveness of our internal control over financial reporting and expect to incur additional expenses and diversion of management's time as a result of performing the system and process evaluation, testing and remediation required in order to comply with the management certification and auditor attestation requirements. Further, implementing any appropriate changes to our internal controls may distract our officers and employees, entail substantial costs to modify our existing processes and take a significant amount of time to complete. Also, during the course of our testing, we may identify other deficiencies that we may not be able to remediate in time to meet the deadline imposed by the Sarbanes-Oxley Act for compliance with the requirements of Section 404.

In addition, if we fail to achieve and maintain the adequacy of our internal controls, as such standards are modified, supplemented or amended from time to time, we may not be able to insure that we can conclude on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act. Moreover, effective internal controls, particularly those related to revenue recognition, are necessary for us to produce reliable financial reports and are important to help prevent financial fraud. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported financial information and the trading price of our common stock, if a market ever develops, could drop significantly.

PERCEIVED BENEFITS

There are certain perceived benefits to being a reporting company with a class of publicly-traded securities. These are commonly thought to include the following:

- the ability to use registered securities to make acquisitions of assets or businesses;
- increased visibility in the financial community;
- the facilitation of borrowing from financial institutions;
- improved trading efficiency;
- shareholder liquidity;

- greater ease in raising capital;
- compensation of key employees through stock options for which there
- may be a market valuation;
- enhanced corporate image; and
- a presence in the United States' capital markets.

SHAREHOLDERS MAY BE DILUTED SIGNIFICANTLY THROUGH OUR EFFORTS TO OBTAIN FINANCING AND SATISFY OBLIGATIONS THROUGH ISSUANCE OF ADDITIONAL SHARES OF OUR COMMON STOCK.

We have no committed source of financing. Wherever possible, our board of directors will attempt to use non-cash consideration to satisfy obligations. In many instances, we believe that the non-cash consideration will consist of restricted shares of our common stock. Our board of directors has authority, without action or vote of the shareholders, to issue all or part of the 988,000,000 authorized, but unissued, shares of our common stock. Future issuances of shares of our common stock will result in dilution of the ownership interests of existing shareholders, may further dilute common stock book value and that dilution may be material.

OUR CERTIFICATE OF INCORPORATION PROVIDES FOR INDEMNIFICATION OF OFFICERS AND DIRECTORS AT OUR EXPENSE AND LIMIT THEIR LIABILITY, WHICH MAY RESULT IN A MAJOR COST TO US AND HURT THE INTERESTS OF OUR SHAREHOLDERS BECAUSE CORPORATE RESOURCES MAY BE EXPENDED FOR THE BENEFITS OF OFFICERS AND/OR DIRECTORS.

Our certificate of incorporation and applicable Nevada laws provide for the indemnification of our directors, officers, employees and agents under certain circumstances, against attorney's fees and other expenses incurred by them in any litigation to which they become a party arising from their association with or activities on our behalf. We will also bear the expenses of such litigation for any of our directors, officers, employees or agents, upon such person's written promise to repay us, therefore, even if it is ultimately determined that any such person shall not have been entitled to indemnification. This indemnification policy could result in substantial expenditures by us that we may be unable to recoup. We have been advised that, in the opinion of the Securities and Exchange Commission, indemnification for liabilities arising under federal securities laws is against public policy and is, therefore, unenforceable. In the event that a claim for indemnification for liabilities arising under federal securities laws, other than the payment by

us of expenses incurred or paid by a director, officer or controlling person in the successful defence of any action, suit or proceeding, is asserted by a director, officer or controlling person in connection with the securities being registered, we will (unless in the opinion of our counsel, the matter has been settled by controlling precedent) submit to a court of appropriate jurisdiction, the question of whether indemnification by us is against public policy as expressed by the Securities and Exchange Commission and will be governed by the final adjudication of such issue. The legal process relating to this matter, if it were to occur, is likely to be very costly and may result in us receiving negative publicity, either of which factors is likely to materially reduce the market price for our shares, if such a market ever develops.

THE ISSUER WAS SUBJECT TO A STATE COURT CUSTODIANSHIP PROCEEDING RECENTLY AND ITS RECORDS MAY NOT BE COMPLETE.

The Issuer was recently subject to a State court custodianship proceeding as an abandoned company and the records of the Issuer may have been lost. The Issuer's custodian and current management may not have all of the records of the Company and thus may be unaware of pending legal actions and other liabilities.

THERE ARE RISKS ASSOCIATED WITH FORWARD LOOKING STATEMENTS

This information statement contains certain forward looking statements regarding management's plans and objectives for future operations including plans and objectives relating to our planned marketing efforts and future economic performance. The forward looking statements and associated risks set forth in this information statement include or relate to, among other things, (a) our projected sales and profitability, (b) our growth strategies, (c) anticipated trends in our industry, (d) our ability to obtain and retain sufficient capital for future operations and (e) our anticipated needs for working capital. These statements may be found under "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Description of Business," in this information statement, as well as in this information statement, generally. Actual events or results may differ materially from those discussed in forward looking statements as a result of various factors, including, without limitation, the risks outlined under "Risk Factors" and matters described in this information statement, generally. In light of these risks and uncertainties, there can be no assurance that the forward looking statements contained in this information statement will, in fact, occur.

CAUTIONARY STATEMENTS REGARDING FORWARD LOOKING STATEMENTS

This information statement contains forward looking statements. These statements relate to future events or future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the Company or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by the forward looking statements. In some cases, you can identify forward looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially. Although we believe that the expectations reflected in the forward looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We are under no duty to update any of the forward looking statements after the date of this information statement to confirm our prior statements to actual results. Further, this information statement contains forward looking statements that involve substantial risks and uncertainties. Such statements include, without limitation, all statements as to expectation or belief and statements as to our future results of operations, the progress of any product development, the need for, and timing of, additional capital and capital expenditures, partnering prospects, the protection of and the need for additional intellectual property rights, effects of regulations, the need for additional facilities and potential market opportunities

Part F. Exhibits

The following exhibits are attached to this disclosure statement: None.

Item XIX. Material Events

On June 27, 2005, Axia Group, Inc. (Axia), entered into a stock purchase Agreement by and among Axia, Jeffrey W. Flannery, and Richard F. Schmidt. Pursuant to the terms of the agreement, Mr. Schmidt sold 150,000 shares of Series C Preferred Stock and 5,000,000 shares of Series D Preferred Stock of Axia to Mr. Flannery.

Also, on June 27, 2005, Richard F. Schmidt resigned as President, Chief Financial Officer, and Secretary of Axia. The board of directors appointed Jeffrey W. Flannery as the new President, Chief Financial Officer, and Secretary.

Thereafter, Richard D. Mangiarelli resigned as a director of Axia. Mr. Schmidt, as the remaining sole director, appointed Mr. Flannery to fill the vacancy on the board of directors.

Item XX. Articles of Incorporation and Bylaws

The Certificate of Incorporation and Bylaws of the Issuer are attached hereto as an Exhibit and are hereby incorporated by reference.

Item XXI. Purchases of Equity Securities by the Issuer and Affiliated Purchasers

The Issuer has made no purchases of Equity Securities


Item XXII. Issuer's Certifications

Certifications

I, Michael Arnkvarn, certify that:

1. I have reviewed this initial disclosure statement of Axia Group, Inc..
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: May 15, 2012



Michael Arnkvarn
Officer

FILED
IN THE OFFICE OF THE
SECRETARY OF STATE OF THE
STATE OF NEVADA

MAR 15 1963

CHERYL A. LADD SECRETARY OF STATE

No. 2791-93

ARTICLES OF INCORPORATION

OF

THE CANTON INDUSTRIAL CORPORATION

copy

FIRST. The name of the Company shall be THE CANTON INDUSTRIAL CORPORATION.

SECOND. The registered agent in the State of Nevada is:

Joseph Alfano
4180 Flaming Crest Drive, #3
Las Vegas, Nevada 89121

THIRD. The purpose or purposes for which the Company is formed are:

(a) To acquire and operate a manufacturing plant for the manufacture of farm equipment;

(b) To manufacture, to purchase, lease, or otherwise acquire, to hold and use, to sell, lease, or otherwise dispose of, and to deal in or with personal property of any description and any interest therein;

(c) To purchase, lease, or otherwise acquire, to invest in, hold, use, and encumber, to sell, lease, exchange, transfer, or otherwise dispose of, and to construct, develop, improve, equip, maintain, and operate structures and real property of any description and any interest therein;

(d) To borrow money, to issue, sell, and pledge its notes, bonds, and other evidences of indebtedness, to

secure any of its obligations by mortgage, pledge, or deed of trust of all or any of its property, and to guarantee and secure obligations of any person, all to the extent necessary, useful, or conducive to carrying out of any of the purposes of the Company;

(e) To invest its funds in any shares or other securities of another corporation, business, or undertaking or of a government, governmental authority, or governmental subdivision; and

(f) To do whatever is deemed necessary, useful, or conducive to carrying out any of the purposes of the Company and to engage in any lawful act or activity for which corporations may be formed under Nevada Corporate Law.

FOURTH. The authorized number of shares of the Company is 8,000,000, all of which are Common Shares with a .001 par value.

FIFTH. The Company, by action of its directors, and without action by its shareholders, may purchase its own shares in accordance with the provisions of the Nevada Revised Statutes. Such purchases may be made either in the open market or at public or private sale, in such manner and amounts, from such holder or holders of outstanding shares of the Company, and at such prices as the directors shall from time to time determine.

SIXTH. No holder of shares of the Company of any class, as such, shall have any pre-emptive right to purchase or subscribe for shares of the Company, of any class, whether now or hereafter authorized.

SEVENTH. The Board of Directors shall consist of no fewer than three members and no more than seven members. The initial Board of Directors will consist of:

Richard Surber
10 West 100 South, Suite 710
Salt Lake City, Utah 84101


Ramon Smullin
10 West 100 South, Suite 710
Salt Lake City, Utah 84101

Alan Hansen
260 East Elm Street
Canton, Illinois 61520


EIGHTH. The incorporator is:


Richard Surber
10 West 100 South, Suite 710
Salt Lake City, Utah 84101

IN WITNESS WHEREOF, I have hereunto subscribed my name on the 23rd day of February, 1993.


Richard Surber, Incorporator

Subscribed and sworn to before me this 23rd day of February, 1993.




Notary Public

required. Also in accordance with NRS 78.207 the Corporation will not be required to reduce or increase its authorized shares in a corresponding ratio in the event of a reverse or forward split

SIXTH. The Corporation, by action of its directors, and without action by its shareholders, may purchase its own shares in accordance with the provisions of Nevada Revised Statutes. Such purchases may be made either in the open market or at public or private sale, in such manner and amounts, from such holder or holders of outstanding shares of the Corporation, and at such prices as the directors shall from time to time determine.

SEVENTH. No holder of shares of the Corporation of any class, as such, shall have any pre-emptive right to purchase or subscribe for shares of the Corporation, of any class, whether now or hereafter authorized.

EIGHTH. The Board of Directors shall consist of no fewer than one member and no more than seven members. The initial Board of Directors will consist of:

Richard Surber
268 West 400 South, Suite 300
Salt Lake City, Utah 84101

Gerald Einhorn
268 West 400 South, Suite 300
Salt Lake City, Utah 84101

The incorporator is:
Richard Surber
268 West 400 South, Suite 300
Salt Lake City, Utah 84101


NINTH. No officer or director shall be personally liable to the corporation or its shareholders for money damages except as provided in Section 78.037, Nevada Revised

Statutes.


TENTH. The corporation shall not issue any non-voting equity securities.

IN WITNESS WHEREOF, these Restated Articles of Incorporation are hereby
made effective

March 21, 2003



Richard Surber
Director and President



Gerald Einhorn
Director and Secretary

FROM : JOHN & SHERY FRY

FAX NO. : 011 52 524 14 10205

Mar. 21 2003 04:27PM P3

MAR/21/2003/FRI 04:07 PM HUDSON CONSULTING

FAX NO. 601570050

P. 008 008

Exhibit A

Approval of the
RESTATED ARTICLES OF INCORPORATION
OF
AXIA GROUP, INC.
(a Nevada corporation)

Pursuant to Section 78.405 of the Nevada Revised Statutes, the undersigned persons, desiring to restate the Articles of Incorporation of Axia Group, Inc. under the laws of the State of Nevada, do hereby sign, verify, and deliver to the Office of the Secretary of State of the State of Nevada this Restatement of the Articles of Incorporation for the above-named company (hereinafter referred to as "Axia"):


Pursuant to the provisions of Section 78.320 the amendment contained herein was duly approved and adopted by a majority of shareholders and by the board of directors of Axia.

WHEREAS, The Articles of Incorporation of Axia were first filed and approved by the Office of the Secretary of the State of Nevada on March 15, 1993:


WHEREAS, The Restated Articles of Incorporation of Axia were adopted by 5,577,792 shares or 52% of the 10,646,873 issued and outstanding shares of common stock entitled to approve such restatements.

THEREFORE BE IT RESOLVED, that the Board of Directors hereby approves the execution and carrying out of the Restatement of the Articles of Incorporation for Axia.

Dated this 18th day of March 2003



Richard Surber, Director

Date: March 18 03



Gerald Einhorn, Director

Date: March 18 03

Approval of the stated action as Shareholders of the Corporation


John Fry, Shareholder

Date: MAR 21 03


Richard Surber, Shareholder

Date: March 18 03

STATE OF NEVADA
Secretary of State
I hereby certify that this is a true and
complete copy of the document as filed
in this office

MAY 12 2003

By _____

[Handwritten Signature]
Deputy Secretary

AXIA GROUP INC.

December 31, 2011

Table of Contents

	Page
Balance Sheet	2
Statement of Earnings and Retained Earnings	3
Statement of Cash Flows	4
Statement of Shareholders' Equity	5
Notes to Financial Statements	6

These financial statements and notes thereto present fairly, in all material respects, the financial position of the company and the results of its operations and cash flows for the period presented, in conformity with accounting principles generally accepted in the United States, consistently applied.

AXIA GROUP INC.
CONSOLIDATED BALANCE SHEET
As at December 31, 2011
(Unaudited)

BALANCE SHEET	
ASSETS	
CURRENT ASSETS	
Cash	\$ 5,629
Accounts Receivable	39,981
Other Receivable	-
Inventory	32,700
Prepaid Accounts	5,610
	83,920
LONG-TERM EQUITY INVESTMENT	-
FIXED ASSETS - NBV	54,844
INTANGIBLE ASSETS - NBV	-
	\$ 138,764
LIABILITIES AND SHAREHOLDERS' EQUITY	
CURRENT LIABILITIES	
Accounts Payable and Accrued Liabilities	\$ 28,101
Bank LOC	36,795
Taxes Payable	-
	64,896
LONG TERM LIABILITIES -	-
	64,896
SHAREHOLDERS' EQUITY	
CAPITAL STOCK	
Common Stock, authorized shares 1,500,000,000 Issued and outstanding - 925,972,018 @ PV \$.00001	9,260
Preferred Stock authorized - 500,000,000 Issued and outstanding - 12,000,000 @ PV \$.00001	120
Paid In Capital	25,619,835
Deficit	- 25,555,347
	73,868
	\$ 138,764

The accompanying notes are an integral part of these
financial statements

AXIA GROUP INC.
CONSOLIDATED STATEMENTS OF EARNINGS AND RETAINED EARNINGS
FOR THE YEAR ENDED December 31, 2011
(Unaudited)

EARNINGS		
REVENUE		
Sales	\$	266,400
		-
TOTAL SALES		<u>266,400</u>
COST OF SALES		
Cost of Sales		60,932
TOTAL COST OF SALES		<u>60,932</u>
GROSS PROFIT		<u>205,468</u>
OPERATING EXPENSES		
Administrative Expense		241,377
Selling Expense		51,658
		<u>293,035</u>
OTHER INCOME & EXPENSES		-
PROFIT (LOSS)		<u>-87,567</u>
NET PROFIT (LOSS)		<u>-87,567</u>
Deficit - Beginning of period	-\$	<u>25,467,780</u>
Deficit - End of period	-\$	<u>25,555,347</u>

The accompanying notes are an integral part of these financial statements

AXIA GROUP INC.
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED December 31, 2011
(Unaudited)

CASH FLOWS	
Cash flows from operating activities	
Profit/Loss from operations	-\$ 87,567
Adjustments to cash flows from operating activities:	
Amortization of goodwill	
Depreciation of fixed assets	-
Cash flows from operating activities	<u>-\$ 87,567</u>
Cash flows from investing activities:	
Capital expenditures	54,844
Investment in inventory	1,705
Increase in accounts receivable	21,284
Increase in prepaid expenses	4,110
Cash used in investing activities	<u>\$ 81,943</u>
Cash flows from financing activities:	
Increase in accounts payable and accrued liabilities	- 81,221
Decrease in paid in capital	539,348
Increase in loans payable	- 31,800
Issuance of capital stock	- 258,805
Cash used for financing activities	<u>\$ 167,522</u>
Net increase (decrease) in cash	-\$ 1,988
Cash at beginning of period	<u>7,617</u>
Cash at end of period	<u>\$ 5,629</u>

The accompanying notes are an integral part of these
financial statements

AXIA GROUP INC.
CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY
AS AT December 31, 2011
(Unaudited)

	Preferred Shares	Stock Amount	Common Shares	Stock&PUC Amount	R/E	Total
Opening Bal	12,000,000	\$120	286,064,762	\$ 25,347,472	-\$ 25,467,780	-\$120,188
Issuance of stk			639,907,256	281,623	-	281,623
Capital Paid In						0
Net Profit/Loss					-	87,567
Bal Dec 2011	12,000,000	\$120	925,972,018	\$ 25,629,095	-\$ 25,555,347	\$73,868

The accompanying notes are an integral part of these
financial statements

AXIA GROUP INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR December 31, 2011
(Unaudited)

NOTE 1. GENERAL ORGANIZATION AND BUSINESS ISSUES

On June 24, 2010, the company announced the sale of their majority shareholder to a European based holding company.

The company and its newly announced management plan to work diligently toward identifying viable merger candidates with high growth potential.

In August 2010, the company announced the purchase of new subsidiary Collagenna Skin Care Products from Hard to Treat Diseases, Inc.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES

Accounting policies and procedures are listed below. The company has adopted a December 31 year end.

Accounting Basis

We have prepared the consolidated financial statements according to generally accepted accounting Principles (GAAP).

Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less as cash equivalents. As of December 31, 2010 the company had no cash or cash equivalent balances in excess of the federally insured amounts. The Company's policy is to invest excess funds in only well capitalized financial institutions.

Earnings per Share

The Company adopted the provisions of SFAS No. 128, "Earnings per Share." SFAS No. 128 requires the presentation of basic and diluted earnings per share ("EPS"). Basic EPS is computed by dividing income available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS includes the potential dilution that could occur if options or other contracts to issue common stock were exercised or converted.

Earnings per Share

The Company adopted the provisions of SFAS No. 128, "Earnings per Share." SFAS No. 128 requires the presentation of basic and diluted earnings per share ("EPS"). Basic EPS is computed by dividing income available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted EPS includes the potential dilution that could occur if options or other contracts to issue common stock were exercised or converted.

The Company has not issued any options or warrants or similar securities since inception.

Stock Based Compensation

As permitted by Statement of Financial Accounting Standards ("SFAS") No. 148, "Accounting for Stock-Based Compensation--Transition and Disclosure", which amended SFAS 123 ("SFAS 123"), "Accounting for Stock-Based Compensation", the Company has elected to continue to follow the intrinsic value method

in accounting for its stock-based employee compensation arrangements as defined by Accounting Principles Board Opinion ("APB") No. 25, "Accounting for Stock Issued to Employees", and related Interpretations including "Financial Accounting Standards Board Interpretations No. 44, Accounting for Certain Transactions Involving Stock Compensation", and interpretation of APB No. 25. At December 31, 2010 the Company has not formed a Stock Option Plan and has not issued any options.

Dividends

The Company has adopted a policy regarding the payment of dividends. Dividends may be paid to shareholders once all divisions are fully operational and profitable. The Board may also pay dividends to counter any short selling or undermining of the entity. See Note 1.

Fixed Assets

Fixed assets are carried at cost. Depreciation is computed using the straight-line method of depreciation over the assets' estimated useful lives. Maintenance and repairs are charged to expense as incurred; major renewals and improvements are capitalized. When items of fixed assets are sold or retired, the related cost and accumulated depreciation is removed from the accounts and any gain or loss is included in income.

Income Taxes

Fixed assets are carried at cost. Depreciation is computed using the straight-line method of depreciation over the assets' estimated useful lives. Maintenance and repairs are charged to expense as incurred; major renewals and improvements are capitalized. When items of fixed assets are sold or retired, the related cost and accumulated depreciation is removed from the accounts and any gain or loss is included in income.

Income Taxes

The provision for income taxes is the total of the current taxes payable and the net of the change in the deferred income taxes. Provision is made for the deferred income taxes where differences exist between the period in which transactions affect current taxable income and the period in which they enter into the determination of net income in the financial statements.

Advertising

Advertising is expensed when incurred.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Goodwill

Goodwill is created when we acquire a business. It is calculated by deducting the fair value of the net assets acquired from the consideration given and represents the value of factors that contribute to greater earning power, such as a good reputation, customer loyalty. We assess goodwill of individual subsidiaries for impairment in the fourth quarter of every year, and when circumstances indicate that goodwill might be impaired.

NOTE 3. GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company had a net loss for the year through to December 31, 2011 of \$ 87,567. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 3. GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company had a net loss for the year through to December 31, 2011 of \$ 87,567. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 4. RECENTLY ISSUED ACCOUNTING STANDARDS

Management does not believe that any recently issued but not yet adopted accounting standards will have a material effect on the Company's results of operations or on the reported amounts of its assets and liabilities upon adoption.

NOTE 5. SHAREHOLDERS' EQUITY

Common Stock:

As of December 31, 2011 the company has 925,972,018 shares of common stock issued and outstanding.

NOTE 6. PROVISION FOR INCOME TAXES

The Company provides for income taxes under Statement of Financial Accounting Standards NO. 109, Accounting for Income Taxes. SFAS No. 109 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse.

SFAS No. 109 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The provision for income taxes is comprised of the net changes in deferred taxes less the valuation account plus the current taxes payable.